BACKGROUND: Cancer-specific mortality is projected to be only 1% in 15 years in approximately 75% of patients with screen-detected localized prostate cancer (LPC). Nearly 94% of patients choose treatment even though treatment damages health-related quality of life. No data are available regarding what survival benefit patients expected from treatment. OBJECTIVES: A self-administered mailed survey was sent to 184 men with newly diagnosed LPC to query patients about expected survival with treatment versus observation. RESULTS: More than 90% of patients had at least a high school education and a ninth-grade health literacy. In addition, 68% patients had income of > or =$50,000. Mean cancer grade was 6.6. Twenty-three patients chose observation and 161 patients chose surgery or radiotherapy. Mean comorbidity adjusted life expectancy (CALE) without the cancer was 22.9 years. Without cancer treatment, 15.2% of patients expected to live <5 years, 48.8% 5 to 10 years, 33.5% 11 to 19 years, and 2.4% > or =20 years. With treatment, survival expectations were <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, and > or =20 years in 62.9% of patients. Age, prostate-specific antigen level, CALE, anxiety, depression, and social support were factors that predicted differences between CALE and patient survival expectations with and without treatment. CONCLUSION: LPC patients grossly underestimated their life expectancy without treatment and grossly overestimated the survival benefit of treatment.
BACKGROUND:Cancer-specific mortality is projected to be only 1% in 15 years in approximately 75% of patients with screen-detected localized prostate cancer (LPC). Nearly 94% of patients choose treatment even though treatment damages health-related quality of life. No data are available regarding what survival benefit patients expected from treatment. OBJECTIVES: A self-administered mailed survey was sent to 184 men with newly diagnosed LPC to query patients about expected survival with treatment versus observation. RESULTS: More than 90% of patients had at least a high school education and a ninth-grade health literacy. In addition, 68% patients had income of > or =$50,000. Mean cancer grade was 6.6. Twenty-three patients chose observation and 161 patients chose surgery or radiotherapy. Mean comorbidity adjusted life expectancy (CALE) without the cancer was 22.9 years. Without cancer treatment, 15.2% of patients expected to live <5 years, 48.8% 5 to 10 years, 33.5% 11 to 19 years, and 2.4% > or =20 years. With treatment, survival expectations were <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, and > or =20 years in 62.9% of patients. Age, prostate-specific antigen level, CALE, anxiety, depression, and social support were factors that predicted differences between CALE and patient survival expectations with and without treatment. CONCLUSION: LPC patients grossly underestimated their life expectancy without treatment and grossly overestimated the survival benefit of treatment.
Authors: Kelvin Koay; Penelope Schofield; Karla Gough; Rachelle Buchbinder; Danny Rischin; David Ball; June Corry; Richard H Osborne; Michael Jefford Journal: Support Care Cancer Date: 2013-03-19 Impact factor: 3.603
Authors: Ravinder Mohan; Hind A Beydoun; May A Beydoun; Myra Barnes-Eley; John Davis; Raymond Lance; Paul Schellhammer Journal: Qual Life Res Date: 2010-12-04 Impact factor: 4.147
Authors: Pierre Lunardi; Guillaume Ploussard; Pascale Grosclaude; Mathieu Roumiguié; Michel Soulié; Jean Baptiste Beauval; Bernard Malavaud Journal: World J Urol Date: 2016-07-21 Impact factor: 4.226
Authors: Jeri Kim; James Ebertowski; Matthew Janiga; Jorge Arzola; Gayle Gillespie; Michael Fountain; Douglas Soderdahl; Edith Canby-Hagino; Sally Elsamanoudi; Jennifer Gurski; John W Davis; Patricia A Parker; Douglas D Boyd Journal: BJU Int Date: 2013-01-25 Impact factor: 5.588
Authors: Jinping Xu; James Janisse; Julie J Ruterbusch; Joel Ager; Joe Liu; Margaret Holmes-Rovner; Kendra L Schwartz Journal: Ann Fam Med Date: 2016-05 Impact factor: 5.166